Physician profile
Shahid S Insaf
NPI 1174666044
$415,711.13
in general payments reported to CMS, 2019-2025
42 companies · $172K in 2025
The $172K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27K · 2020: $8,053 · 2021: $22K · 2022: $20K · 2023: $69K · 2024: $98K · 2025: $172K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $117K · Honoraria: $74K · Consulting Fee: $69K · Travel and Lodging: $60K · Food and Beverage: $19K · Education: $205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $116,730.00 |
| Honoraria | $74,400.00 |
| Consulting Fee | $69,042.50 |
| Travel and Lodging | $59,961.85 |
| Food and Beverage | $19,047.07 |
| Education | $204.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $120,154.93 | 2022-2025 | Auvelity, Sunosi |
| Alkermes, INC. | $114,822.34 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| Supernus Pharmaceuticals, INC. | $77,239.27 | 2021-2025 | Qelbree, Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $51,639.84 | 2020-2025 | Caplyta |
| Allergan, INC. | $29,840.34 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $3,409.04 | 2019-2025 | Austedo Xr, Uzedy, Austedo |
| Abbvie INC. | $3,265.13 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $2,178.36 | 2024-2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $1,707.08 | 2019-2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $1,638.84 | 2019-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $1,588.72 | 2019-2025 | Nuedexta, Rexulti, Abilify Maintena |
| Sunovion Pharmaceuticals INC. | $1,413.21 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $1,310.09 | 2019-2022 | |
| Corium, LLC | $802.73 | 2022-2025 | Azstarys |
| Lundbeck LLC | $689.35 | 2019-2025 | Rexulti |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shahid Insaf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.